PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16555688

Clazosentan (Actelion).

Dirk Uhlmann
View original source ↗Export metadata ↓

Abstract

Clazosentan, an endothelin ETA antagonist, is under development by Actelion (formerly Axovan), under license from F Hoffman-La Roche, for the potential prevention of cerebral infarction and ischemia induced by cerebral vasospasm following subarachnoid hemorrhage. Results from the phase IIb portion of a phase IIb/III clinical study are expected in the first half of 2006.

Explore related subjects

Clinical Trials, Phase III as TopicDioxanesEndothelin-1HumansMolecular ConformationPyridinesPyrimidinesSubarachnoid HemorrhageSulfonamidesTetrazolesVasoconstrictionVasoconstrictor AgentsVasospasm, IntracranialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Dirk Uhlmann. 2006. Clazosentan (Actelion).. https://pubmed.ncbi.nlm.nih.gov/16555688/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Squalene synthase inhibition: a novel target for the management of dyslipidemia.

A new class of compounds, known as squalene synthase inhibitors, has recently reached phase III clinical trials and may provide another therapeutic option for clinicians to improve risk management of low-density lipoprotein cholesterol (LDL-C). The clinical need for another LDL-C-lowering therapy is evident by the inability to achieve an LDL-C target of less than 70 mg/dL in the majority of very high-risk patients on statin monotherapy. Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published.

Clinical Trials, Phase III as Topic↗
PubMed2006

[Herpes simplex virus vaccines: perspectives].

PURPOSE: Despite effective antiviral therapy, infection with herpes simplex virus (HSV) is a critical public health issue, particularly genital herpes by its social and psychological burden and its contribution to the neonatal herpes and possibly to the HIV/AIDS pandemic. CURRENT KNOWLEDGE: Many prophylactic and therapeutic vaccination approaches have been explored but no effective vaccine is presently available. In fact, as members of the Herpesviridae family, both HSV-1 and 2 types have genes involved in immune evasion. FUTURE PROSPECTS: Further research is needed to define determinants of immunity in order to design more effective vaccines.

Clinical Trials, Phase III as Topic↗